Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Literature
1.
2.
Economopoulos KP, Sergentanis TN. Differential effects of mdm2 snp309 polymorphism on breast cancer risk along with race: a meta-analysis. Breast Cancer Res Treat. 2010;120:211–6.CrossRefPubMed
3.
Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. Mdm2 promoter polymorphism snp309 contributes to tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev. 2007;16:2717–23.CrossRefPubMed
4.
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in the mdm2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602.CrossRefPubMed
5.
Knappskog S, Bjornslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, et al. The mdm2 promoter snp285c/309 g haplotype diminishes sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians. Cancer Cell. 2011;19:273–82.CrossRefPubMed
6.
Knappskog S, Lonning PE. Mdm2 promoter snp285 and snp309; phylogeny and impact on cancer risk. Oncotarget. 2011;2:251–8.PubMedCentralPubMed
7.
Knappskog S, Trovik J, Marcickiewicz J, Tingulstad S, Staff AC, MoMa TECsg, et al. Snp285c modulates oestrogen receptor/sp1 binding to the mdm2 promoter and reduces the risk of endometrial but not prostatic cancer. Eur J Cancer. 2012;48:1988–96.CrossRefPubMed
Metadata
Title
MDM2 SNP309 and risk of cervical cancer
Authors
Stian Knappskog
Per Eystein Lønning
Publication date
01-07-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1910-4

Other articles of this Issue 7/2014

Tumor Biology 7/2014 Go to the issue

Research Article

Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies

Research Article

AQP5 silencing suppresses p38 MAPK signaling and improves drug resistance in colon cancer cells

Research Article

MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells

Research Article

Association between IRS-1 Gly972Arg polymorphism and colorectal cancer risk

Research Article

Quercetin and hyperthermia modulate cisplatin-induced DNA damage in tumor and normal tissues in vivo

Research Article

Concomitant upregulation of nucleostemin and downregulation of Sox2 and Klf4 in gastric adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits